BPC-157: Evidence, Legal Status, and Safety
BPC-157 is the most popular “research peptide” on the market, but the human evidence does not match the hype. Almost all of the evidence is animal and preclinical; the only human trial in progress (a hamstring-strain study) is still recruiting, not reporting results. It is not FDA-approved for any human use, sold as an unregulated research chemical, and banned at all times under WADA's anti-doping rules.
Understand what's actually being sold A synthetic fragment derived from a peptide first isolated from human gastric juice, promoted for tendon, ligament, gut, and wound healing, often marketed as a “Wolverine stack” alongside TB-500.
The marketing framing (“Wolverine stack”) is a branding term from self-experimenters, not a clinical designation.
See what the human evidence actually is Almost all evidence is animal and preclinical. One human trial is currently recruiting (ClinicalTrials.gov NCT07437547, acute hamstring strain) but has not reported results. No completed, published human RCT with efficacy outcomes was independently verified.
Popularity and an in-progress trial do not raise a peptide's evidence tier; this stays Tier C until a completed human RCT reports a result.
Know where it actually stands Not FDA-approved for any human use; sold almost exclusively as an unregulated “research chemical, not for human consumption.” On 23 Jul 2026, the FDA's Pharmacy Compounding Advisory Committee recommended BPC-157 for compounding (reported 8-6 by trade press), but that recommendation is advisory only: nothing is legal today, and formal rulemaking has not started. Banned at all times under WADA's code (S0 and S2 categories).
“Legal to buy as a research chemical” is not the same thing as “approved as a medical product,” and a substance can be both gray-market to purchase and career-ending to test positive for.
Know the real risk No FDA safety review exists for human use. The FDA's own restricted-compounding flag raised concerns about potential immune reactions, unknown long-term safety, and impurity risk from unregulated manufacturing. Because BPC-157's proposed mechanism involves promoting tissue growth and blood-vessel formation, there is a theoretical, unproven concern about tumor-growth-promoting effects that Andrew Huberman has specifically flagged. Gray-market vials carry no quality-control guarantee.
A mechanism that promotes tissue growth cuts both ways: it's the proposed benefit and the proposed risk.
The evidence base is overwhelmingly animal and preclinical: a 2025 systematic review of BPC-157 in orthopaedic sports medicine and a 2023 literature and patent review are both explicit that human clinical evidence is sparse.
View sources
USADA: BPC-157, a Prohibited Peptide
Peter Attia, AMA #83: Peptides, evaluating the science, safety, and hype (BPC-157 named his “weakest evidence bucket”)
Huberman Lab: Benefits & Risks of Peptide Therapeutics for Physical & Mental Health (BPC-157 segment)
BPC-157 for Acute Hamstring Muscle Strain Repair (ClinicalTrials.gov NCT07437547, currently recruiting)
Emerging Use of BPC-157 in Orthopaedic Sports Medicine (systematic review, 2025)
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.
Is this for you
- Anyone considering BPC-157 who wants the honest evidence before discussing it with a clinician
- Athletes checking WADA and anti-doping status
- Readers who have seen “Wolverine stack” claims and want the actual trial evidence
- Readers comparing BPC-157 to FDA-approved peptides like semaglutide or tesamorelin
Cautions
- Not FDA-approved for any human use; sold as an unregulated research chemical with no purity or sterility guarantee.
- Banned at all times under WADA's anti-doping code (S0 and S2); can result in a competition ban if detected.
- Human safety and efficacy data is essentially absent; one relevant trial is recruiting, not reporting results.
- Educational only, not medical advice.